A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10525-10525
Author(s):  
Stefano Ferrari ◽  
Paolo G Casali ◽  
Jean-Yves Blay ◽  
Axel Le Cesne ◽  
Tonini Giuseppe ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
Randomized Phase Ii

scholarly journals Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

1998 ◽  
Vol 9 (8) ◽  
pp. 871-876 ◽  
Author(s):  
J.M. Buesa ◽  
A. López-Pousa ◽  
J. Martín ◽  
A. Antón ◽  
J. García del Muro ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
First Line

scholarly journals Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)

Sarcoma ◽  
2006 ◽  
Vol 2006 ◽  
pp. 1-8 ◽  
Author(s):  
A. López-Pousa ◽  
J. Martín ◽  
J. Montalar ◽  
R. de las Peñas ◽  
J. García del Muro ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Febrile Neutropenia ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
Substantial Toxicity ◽  
Grade 3

Background.To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m2every 4 weeks in patients with soft tissue sarcomas.Methods.DXR was given IV bolus and IFOS by continuous infusion at 2 g/m2/day. Initial IFOS dose (12 g/m2) was adjusted to 10, 13, or 14 g/m2according to toxicity.Results.Seventy patients received 277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose increased, 30% decreased, and 48% delivered at 12 g/m2. Toxicity grade 4 occurred on granulocytes (67% of patients) or platelets (19%), 54% had febrile neutropenia, 31% grade 3/4 asthenia, and 26% abandoned the study due to toxicity. Three toxic deaths occurred. In 57 non-GIST patients objective activity was 45.6% (95% CI, 32 to 58%).Conclusion.At least 4 cycles were tolerated by 71% of patients, most receiving DXR 50 mg/m2plus IFOS 10–12 g/m2, with substantial toxicity.

Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas

1986 ◽  
Vol 18 (S2) ◽  
pp. S13-S16 ◽  
Author(s):  
Vivien H. C. Bramwell ◽  
◽  
H. T. Mouridsen ◽  
A. Santoro ◽  
G. Blackledge ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Preliminary Report ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
Randomized Phase Ii

NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10526-10526 ◽  
Author(s):  
Zeynep Eroglu ◽  
Hussein Abdul-Hassan Tawbi ◽  
James Hu ◽  
Min Guan ◽  
Paul Henry Frankel ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
Randomized Phase Ii

Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas

1987 ◽  
Vol 23 (3) ◽  
pp. 311-321 ◽  
Author(s):  
Vivien H.C. Bramwell ◽  
H.T. Mouridsen ◽  
A. Santoro ◽  
G. Blackledge ◽  
R. Somers ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas ◽  
Final Report ◽  
Randomized Phase Ii

scholarly journals Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups

2019 ◽  
Vol 30 ◽  
pp. v686-v687
Author(s):  
J Martin Broto ◽  
A. Italiano ◽  
R M Alvarez Alvarez ◽  
I. Rincon ◽  
J. Peinado ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Phase Ii ◽  
Low Dose ◽  
Phase Ii Trial ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document